254 Results for "

pg-ps

" in MedChemExpress (MCE) Product Catalog:
Products (254)

254 Results for "pg-ps" in MCE Product Catalog:

Cat. No.: HY-119823
CAS No.: 365565-02-2
Purity:  99.69%
Target:  

P-glycoprotein

Research Areas:  

Cancer

PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin .
loading...
    loading...
Cat. No.: HY-173162
CAS No.: 86383-89-3
GPV0057 (Compound 5d) is a selective and potent P-glycoprotein (P-gp) inhibitor. GPV0057 is also a selective potassium channel Kir2.1 activator. GPV0057 competitively binds to the substrate-binding site of P-gp, inhibiting ATP-dependent drug efflux to reverse multidrug resistance in tumor cells. GPV0057 can also stabilizes the open state of Kir2.1 and promotes potassium ion influx. GPV0057 is promising for research of tumors with high P-gp expression, Kir2.1-deficient diseases such as heart failure and Andersen-Tawil Syndrome .
loading...
    loading...
Cat. No.: HY-B0777S
Synonyms: CL-301423-d3
Moxidectin-d3 (CL-301423-d3) is deuterium labeled Moxidectin. Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .
loading...
    loading...
Cat. No.: HY-132866
CAS No.: 2470908-79-1
Purity:  98.07%
Target:  

P-glycoprotein

Research Areas:  

Cancer

YS-370 (compound 44) is a potent, high selective, and orally active inhibitor of P-glycoprotein (P-gp). YS-370 stimulates the P-gp ATPase activity and has moderate inhibition against CYP3A4. YS-370 effectively reverses multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 in combination with paclitaxel achieves much stronger antitumor activity .
loading...
    loading...
Cat. No.: HY-10550R
CAS No.: 206873-63-4
Synonyms: XR9576 (Standard)
Research Areas:  

Cancer

Tariquidar (Standard) is the analytical standard of Tariquidar. This product is intended for research and analytical applications. Tariquidar (XR9576) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (Kd=5.1 nM) .
loading...
    loading...
Cat. No.: HY-N4108
CAS No.: 33676-00-5
Hypophyllanthin is a major lignan in Phyllanthus spp, with strong anti-inflammatory activity. Hypophyllanthin directly inhibits P-glycoprotein (P-gp) activity and did not interfere with multidrug resistance protein 2 (MRP2) activity .
loading...
    loading...
Cat. No.: HY-19626
CAS No.: 858474-14-3
Target:  

P-glycoprotein

Research Areas:  

Cancer

NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor.
loading...
    loading...
Cat. No.: HY-101791
CAS No.: 2050747-49-2
Purity:  98.79%
Target:  

P-glycoprotein

Research Areas:  

Cancer

P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.
loading...
    loading...
Cat. No.: HY-175838
CAS No.: 2918249-59-7
Target:  

P-glycoprotein

Research Areas:  

Cancer

P-gp-IN-32 is a P-glycoprotein (P-gp) inhibitor. P-gp-IN-32 exhibits low cytotoxicity and potent multidrug resistance (MDR) reversal activity against Doxorubicin (HY-15142A) in MCF7/ADR cells (IC50 = 0.11 μM, reversal fold (RF) = 215.9). P-gp-IN-32 can bind to P-gp directly, induce a conformation change of P-gp and inhibit the efflux function. P-gp-IN-32 can be used for the research of cancer, such as breast cancer .
loading...
    loading...
Cat. No.: HY-149277
CAS No.: 1807320-40-6
Target:  

P-glycoprotein

Research Areas:  

Cancer

FM04 is a potent P-glycoprotein (P-gp) inhibitor (EC50=83 nM). FM04 inhibits P-gp in 2 mechanism: (1)FM04 binds to Q1193, followed by interacting with the functionally critical residues H1195 and T1226; or (2)FM04 binds to I1115 (a functionally critical residue itself), disrupting the R262-Q1081-Q1118 interaction pocket and uncoupling ICL2-NBD2 interaction and thereby inhibiting P-gp .
loading...
    loading...
Cat. No.: HY-W001601
CAS No.: 57982-78-2
Target:  

iGluR

Research Areas:  

Neurological Disease

Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .
loading...
    loading...
Cat. No.: HY-110377
CAS No.: 1992047-62-7
Synonyms: XR9576 dihydrochloride
Target:  

P-glycoprotein

Research Areas:  

Cancer

Tariquidar dihydrochloride (XR9576 dihydrochloride) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (Kd=5.1 nM) .
loading...
    loading...
Cat. No.: HY-144366
CAS No.: 2766451-11-8
Target:  

P-glycoprotein

Research Areas:  

Cancer

P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .
loading...
    loading...
Cat. No.: HY-178349
Research Areas:  

Cancer

P-gp inhibitor 30 is a potent P-gp inhibitor that reverses multidrug resistance in breast cancer by sensitizing resistant cells to Doxorubicin (ADM) (HY-15142). P-gp inhibitor 30 promotes apoptosis, induces autophagy, and suppresses proliferation, migration, and invasion of drug-resistant breast cancer cells when combined with ADM. P-gp inhibitor 30 inhibits breast tumor growth both in vitro and in vivo. P-gp inhibitor 30 can be used for drug-resistant breast cancer research .
loading...
    loading...
Cat. No.: HY-U00247
CAS No.: 140646-80-6
Target:  

P-glycoprotein

Research Areas:  

Cancer

MCI826 is a P-glycoprotein (P-gp) antagonist.
loading...
    loading...
Cat. No.: HY-146391
CAS No.: 2652001-05-1
Target:  

P-glycoprotein

Research Areas:  

Cancer

P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC50 of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .
loading...
    loading...
Cat. No.: HY-123384
CAS No.: 205535-74-6
Target:  

P-glycoprotein

Research Areas:  

Cardiovascular Disease Cancer

KR30031, a Verapamil (HY-14275) analog, is an orally active P-glycoprotein (P-gp) inhibitor. KR30031 enhances the cytotoxicity of anticancer agents by inhibiting P-gp with fewer cardiovascular adverse effects. KR30031 can be used to study multidrug resistance (MDR) reversal in cancer .
loading...
    loading...
Cat. No.: HY-128685
CAS No.: 1451741-22-2
Synonyms: Ac12Az9
Target:  

P-glycoprotein BCRP

Research Areas:  

Cancer

FD 12-9 is a flavonoid dimer, acts as a dual inhibitor of P-gp and BCRP, with EC50s of 285 nM and 0.9 nM, respectively. Anti-glioblastoma activity .
loading...
    loading...
Cat. No.: HY-107197
CAS No.: 34125-75-2
Target:  

P-glycoprotein

Research Areas:  

Cancer

8-prenylchrysin is a C8-prenylated flavonoid. 8-prenylchrysin inhibits P-gp. 8-prenylchrysin can be used for tumor research .
loading...
    loading...
Cat. No.: HY-W035709R
CAS No.: 485-65-4
Synonyms: Dihydrocinchonine (Standard)
Hydrocinchonine (Dihydrocinchonine) (Standard) is the analytical standard of Hydrocinchonine (HY-W035709). This product is used for research and analytical purposes.Hydrocinchonine is a multidrug resistance (MDR)-reversal agent. Hydrocinchonine directly inhibits the function and expression of P-gp, which is the mechanism by which it reverses MDR. Hydrocinchonine exerts synergistic apoptotic effect with Paclitaxel (HY-B0015) in MES-SA/DX5 cells. Hydrocinchonine can be used for the study of gynecological malignant tumors (such as uterine sarcoma) with drug resistance caused by excessive expression of P-gp .
loading...
    loading...